'For the quarter ending June 2021, Net sales (including other operating income) of Glenmark Pharmaceuticals has increased 26.45% to Rs 2964.9 crore compared to quarter ending june 2020.
Operating profit margin has fell from 20.39% to 19.35%, leading to 19.98% rise in operating profit to Rs 573.58 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 31.13% to 29.96%. Purchase of finished goods cost rose from 0.96% to 10.41%. Employee cost decreased from 22.53% to 19.48%. Other expenses fell from 24.26% to 21.42%.
Other income rose 0.24% to Rs 58.65 crore. PBIDT rose 17.83% to Rs 632.23 crore. Provision for interest fell 19.35% to Rs 75.6 crore.
PBDT rose 25.70% to Rs 556.63 crore. Provision for depreciation fell 0.13% to Rs 113.07 crore.
Profit before tax grew 34.57% to Rs 443.56 crore. Shar...
Pleaselogin & subscribe to view the full report.
More Reports
|
|